|
US4626539A
(en)
|
1984-08-10 |
1986-12-02 |
E. I. Dupont De Nemours And Company |
Trandermal delivery of opioids
|
|
CA2002299A1
(en)
|
1988-11-10 |
1990-05-10 |
Eugene G. Drust |
Compositions for the transdermal delivery of buprenorphine salts
|
|
FR2735658B1
(en)
|
1995-06-21 |
1997-09-12 |
Capsulis |
ENCAPSULATION OF COMPOUNDS FOR FOOD USE WITH SURFACTANTS
|
|
IL113303A0
(en)
|
1994-04-08 |
1995-07-31 |
Brigham & Womens Hospital |
Treatment of autoimmune disease using oral tolerization and/or type I interferon
|
|
GB9516268D0
(en)
|
1995-08-08 |
1995-10-11 |
Danbiosyst Uk |
Compositiion for enhanced uptake of polar drugs from the colon
|
|
AU1031500A
(en)
|
1998-11-03 |
2000-05-22 |
Dandy A/S |
Sucrose fatty acid esters for use as increased release of active ingredients
|
|
KR100383252B1
(en)
|
1998-12-17 |
2003-07-16 |
주식회사 삼양사 |
Transdermal Dosage Compositions Containing Buprenoline and Patches Comprising the Same
|
|
CZ20023009A3
(en)
|
2000-03-08 |
2003-06-18 |
Awd. Pharma Gmbh & Co. Kg |
Pharmaceutical preparations
|
|
AU2004258894B2
(en)
|
2003-07-17 |
2010-06-03 |
Patheon Softgels Inc. |
Controlled release preparations
|
|
IL159729A0
(en)
|
2004-01-06 |
2004-06-20 |
Doron I Friedman |
Non-aqueous composition for oral delivery of insoluble bioactive agents
|
|
ES2653568T3
(en)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Drug formulations for abuse prevention
|
|
US20160184258A1
(en)
|
2005-11-07 |
2016-06-30 |
Murty Pharmaceuticals, Inc. |
Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
|
|
GB0606124D0
(en)
|
2006-03-28 |
2006-05-03 |
Reckitt Benckiser Healthcare |
Buprenorphine derivatives and uses thereof
|
|
DE102006054731B4
(en)
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal therapeutic system for administration of the active ingredient buprenorphine and use thereof in pain therapy
|
|
US20090047336A1
(en)
|
2007-08-17 |
2009-02-19 |
Hong Kong Baptist University |
novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
|
|
ES2572157T3
(en)
|
2007-09-03 |
2016-05-30 |
Nanotherapeutics Inc |
Compositions in the form of particles for the administration of poorly soluble drugs
|
|
US20110097395A1
(en)
|
2008-03-08 |
2011-04-28 |
Najib Babul |
Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
|
|
ES2629131T3
(en)
|
2008-09-17 |
2017-08-07 |
Chiasma Inc. |
Pharmaceutical compositions and related delivery methods.
|
|
US20110142889A1
(en)
|
2009-12-16 |
2011-06-16 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
|
CN102579340B
(en)
|
2011-01-07 |
2016-03-02 |
北京因科瑞斯医药科技有限公司 |
Sinomenine vesicle and preparation thereof and preparation method
|
|
DK2915525T3
(en)
|
2011-09-19 |
2021-08-23 |
Orexo Ab |
Sublingual abuse-resistant tablets comprising buprenorphine and naloxone
|
|
EA201491164A1
(en)
|
2011-12-12 |
2014-10-30 |
ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ |
TRANSDERMAL SYSTEM SUPPLIES
|
|
WO2014031958A1
(en)
|
2012-08-24 |
2014-02-27 |
Integurx Therapeutics, Llc |
Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
|
|
AU2013205080B2
(en)
|
2012-12-12 |
2016-07-07 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal Delivery System
|
|
US10420729B2
(en)
|
2013-03-15 |
2019-09-24 |
R.P. Scherer Technologies, Llc |
Abuse resistant capsule
|
|
CA2908583A1
(en)
|
2013-04-08 |
2014-10-16 |
Virginia Commonwealth University |
Compositions to alleviate presystemic metabolism of opioids
|
|
PL2810646T3
(en)
|
2013-06-04 |
2017-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermal delivery system
|
|
US9326980B2
(en)
|
2013-07-21 |
2016-05-03 |
Kimia Zist Parsian (Kzp) |
Method and system for synthesizing nanocarrier based long acting drug delivery system for buprenorphine
|
|
WO2015103379A1
(en)
|
2013-12-31 |
2015-07-09 |
Kashiv Pharma, Llc |
Abuse-resistant drug formulations
|
|
WO2015193380A2
(en)
|
2014-06-19 |
2015-12-23 |
Solural Pharma ApS |
Solid oral dosage form of lipophilic compounds
|
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
|
WO2016022936A1
(en)
|
2014-08-07 |
2016-02-11 |
Murty Pharmaceuticals, Inc. |
An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
|
|
WO2016120378A1
(en)
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Tablets comprising glp-1 agonist and enteric coating
|
|
WO2017048595A1
(en)
|
2015-09-14 |
2017-03-23 |
Amneal Pharmaceuticals Llc |
Transdermal delivery system
|
|
US20170312226A1
(en)
|
2016-04-28 |
2017-11-02 |
Ascent Pharmaceuticals, Inc. |
Pharmaceutical dosage forms
|
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
|
US20190015346A1
(en)
|
2017-07-14 |
2019-01-17 |
Pharmacannis Labs Llc |
Self-emulsifying drug delivery system
|
|
WO2019064026A1
(en)
*
|
2017-09-29 |
2019-04-04 |
Orexo Ab |
New pharmaceutical compositions
|